Academic degree 【 display / non-display 】

Academic degree 【 display / non-display 】

Research Areas 【 display / non-display 】

Research Areas 【 display / non-display 】

Published Papers 【 display / non-display 】

Published Papers 【 display / non-display 】

• Prognostic Factors of Cervical Adenocarcinoma With Positive Pelvic Lymph Node Metastases Without Preoperative Lymph Node Enlargement Treated With Radical Hysterectomy.

  Watanabe T, Tamashiro N, Shimoji Y, Arakaki Y, Taira Y, Nakamoto T, Kudaka W, Aoki Y

  Cancer diagnosis & prognosis   3 ( 1 ) 96 - 101   2023.01 [ Peer Review Accepted ]

  Type of publication: Research paper (scientific journal)

  • Access this article
    DOI
  • Search related information
    PubMed

• Low-set umbilicus in a pregnant woman with bladder pseudoexstrophy: A case report.

  Taira Y, Yara N, Kinjo Y, Kinjo T, Mekaru K, Aoki Y

  Case reports in women's health ( Case Reports in Women's Health )  36   e00467   2022.10 [ Peer Review Accepted ]

  Type of publication: Research paper (other science council materials etc.)

  　View Summary

  Bladder pseudoexstrophy is a rare form of bladder exstrophy. Bladder exstrophy occurs in 1 in every 30,000 to 50,000 live births. Because bladder pseudoexstrophy is asymptomatic, it may be undiagnosed even in adulthood. A 31-year-old woman with uterus bicornis unicollis and a low-set umbilicus underwent emergency cesarean delivery during the 37th week of pregnancy for chorioamnionitis. Perioperatively, asymptomatic anatomical abnormalities were identified, which included separated rectus abdominis muscles and diastasis of the symphysis pubis. The urinary tract was normal. The patient was diagnosed with bladder pseudoexstrophy. A low-set umbilicus may be a potential marker for the diagnosis of bladder pseudoextrophy.

  • Access this article
    DOI
  • Search related information
    PubMed

• Effects of Pegylated Liposomal Doxorubicin and CA125 Level Variability Analysis in Platinum-refractory/resistant Recurrent Ovarian Cancer.

  Ooyama T, Shimoji Y, Nakasone T, Arakaki Y, Taira Y, Nakamoto T, Kudaka W, Aoki Y

  Anticancer research ( Anticancer Research )  42 ( 6 ) 3017 - 3022   2022.06 [ Peer Review Accepted ]

  Type of publication: Research paper (scientific journal)

  　View Summary

  BACKGROUND/AIM: Ovarian cancer is a disease with significant impact, because more than half of cases exhibit recurrence despite platinum therapy. The choice of drug for cases of recurrence remains controversial, but the current option is pegylated liposomal doxorubicin (PLD). PATIENTS AND METHODS: We retrospectively reviewed the use of PLD in patients with ovarian cancer refractory or resistant to platinum-based therapy at our Department. We also examined efficacy, predictive indices of efficacy, and adverse events as well. RESULTS: In this study of PLD monotherapy for 60 platinum-refractory/resistant recurrent ovarian cancers, there was a median progression-free survival (PFS) of 4 months, median overall survival (OS) of 11 months, and the disease control rate (DCR) was 71.7%. The treatment effect can be predicted by the reduction of CA125 level after 2 courses. Patients with an increase and decrease in CA125 after 2 cycles of PLD, respectively, had a median OS of 14.5 (2-60) and 8 (2-51) months and a median PFS of 6 (2-38) months and 3 (0-47) months. CONCLUSION: PLD is clinically effective and useful because it provides a high DCR and is tolerable to adverse events. These findings can help support the use of PLD and guide physicians in their choice of treatment when encountering such cases.

  • Access this article
    DOI
  • Search related information
    PubMed

• Paclitaxel-carboplatin and bevacizumab combination with maintenance bevacizumab therapy for metastatic, recurrent, and persistent uterine cervical cancer: An open-label multicenter phase II trial (JGOG1079).

  Tanigawa T, Takeshima N, Ishikawa H, Nishio S, Usami T, Yamawaki T, Oishi T, Ihira K, Kato H, Goto M, Saito M, Taira Y, Yokoyama M, Shoji T, Kondo E, Mori A, Yokoi T, Iwasa-Inoue N, Hirashima Y, Nagasawa T, Takenaka M, Mikami M, Sugiyama T, Enomoto T

  Gynecologic oncology ( Gynecologic Oncology )  165 ( 3 ) 413 - 419   2022.06 [ Peer Review Accepted ]

  Type of publication: Research paper (scientific journal)

  　View Summary

  OBJECTIVE: This multicenter, open-label, phase II study aimed to evaluate the efficacy and safety of paclitaxel-carboplatin, bevacizumab, and bevacizumab-based maintenance therapy for metastatic, recurrent, and persistent uterine cervical cancer. METHODS: Patients with measurable diseases that were not adapted to regional therapies, such as surgery or radiotherapy, and were systematic chemotherapy-naïve were eligible. The participants received paclitaxel (175 mg/m2), carboplatin (AUC 5), and bevacizumab (15 mg/m2) every three weeks until disease progression or unacceptable adverse events occurred. The primary endpoint was progression-free survival (PFS). The secondary endpoints were overall response rate (ORR), overall survival (OS), safety, and time to treatment failure. RESULTS: Sixty-nine patients were analyzed using our protocol. The median paclitaxel- carboplatin therapy duration was six cycles; 40% of patients received bevacizumab maintenance therapy. The median PFS was 11.3 months. The median OS was not reached; the median time to treatment failure was 5.9 months. The ORR was 79.7% [95% confidence interval (CI) 63.8-88.4]; 16 patients (23.2%) showed complete response (CR) and 39 patients (56.5%) showed partial response (PR). The median PFS was 14.3 months (95% CI 7.3-17 months) for the 25 patients who received maintenance therapy and 7.4 months (95% CI 6.1-11 months) for nonrecipients (p = 0.0449). Gastrointestinal perforation/fistulas occurred in four patients (5.6%), all of whom had a history of radiation therapy. CONCLUSIONS: Paclitaxel-carboplatin and bevacizumab therapy is an acceptable and tolerable treatment for advanced or recurrent cervical cancer.

  • Access this article
    DOI
  • Search related information
    PubMed

• Changes in HPV16/18 Prevalence among Unvaccinated Women with Cervical Intraepithelial Neoplasia in Japan: Assessment of Herd Effects following the HPV Vaccination Program.

  Onuki M, Yamamoto K, Yahata H, Kanao H, Horie K, Konnai K, Nio A, Takehara K, Kamiura S, Tsuda N, Takei Y, Shigeta S, Nakai H, Yoshida H, Motohara T, Kato T, Nakamura K, Hamanishi J, Tasaka N, Ishikawa M, Kado N, Taira Y, Mori M, Iwata T, Takahashi F, Kukimoto I, Yoshikawa H, Yaegashi N, Matsumoto K, For The Mint Study Group

  Vaccines ( Vaccines )  10 ( 2 )   2022.01 [ Peer Review Accepted ]

  Type of publication: Research paper (scientific journal)

  　View Summary

  Since the human papillomavirus (HPV) vaccination program for Japanese girls aged 12-16 years began in 2010, vaccination uptake has been low in women born before 1993 but high (approximately 70%) in those born during 1994-1999. We previously compared the prevalence of vaccine types HPV16 and HPV18 in cervical intraepithelial neoplasia grade 1-3 (CIN1-3) or adenocarcinoma in situ (AIS) between vaccinated and unvaccinated cohorts and found direct protection effects among vaccinated women in Japan. In this study, we focused on changes in HPV16/18 prevalence among "unvaccinated" cohorts with CIN/AIS. We analyzed HPV16/18 prevalence among 5051 unvaccinated women aged <40 years, newly diagnosed with CIN/AIS during 2012-2021 for time trends. Declining trends in HPV16/18 prevalence over 9 years were observed in CIN1 (36.0-10.0%, Ptrend = 0.03) and CIN2-3/AIS (62.5-36.4%, Ptrend = 0.07) among women aged <25 years. HPV16/18 prevalence in CIN1 and CIN2-3/AIS diagnosed at age 20-24 years was lower in 1994-1999 birth cohorts compared with 1988-1993 birth cohorts (4.5% vs. 25.7% for CIN1 and 40.0% vs. 58.1% for CIN2-3/AIS, both p = 0.04). Significant reduction in HPV16/18 prevalence among young unvaccinated women with CIN1 and CIN2-3/AIS suggests herd effects of HPV vaccination in Japan.

  • Access this article
    DOI
  • Search related information
    PubMed

display all >>

Other Papers 【 display / non-display 】

Other Papers 【 display / non-display 】

• 当科で経験した直腸腟中隔原発の扁平上皮癌3症例

  新垣 精久, 渡部 俊陽, 大木 悠司, 下地 裕子, 仲宗根 忠栄, 平良 祐介, 仲本 朋子, 久高 亘, 青木 陽一

  日本癌治療学会学術集会抄録集 ( (一社)日本癌治療学会 )  59回   P26 - 3   2021.10

   

• 子宮頸癌に対する放射線療法の外来/入院治療の比較

  下地 裕子, 仲宗根 忠栄, 新垣 精久, 平良 祐介, 仲本 朋子, 大山 拓真, 久高 亘, 青木 陽一

  日本癌治療学会学術集会抄録集 ( (一社)日本癌治療学会 )  57回   P32 - 3   2019.10

   

• 当科で経験した子宮体部脱分化癌2症例

  平良 祐介, 下地 裕子, 仲宗根 忠栄, 新垣 精久, 仲本 朋子, 大山 拓真, 久高 亘, 青木 陽一

  日本癌治療学会学術集会抄録集 ( (一社)日本癌治療学会 )  57回   P31 - 3   2019.10

   

• 子宮内膜癌の孤発性腟再発に関する臨床転帰(Clinical outcomes of isolated vaginal recurrences of endometrial cancer)

  Nakamoto Tomoko, Yamada Hisako, Shimoji Yuko, Nakasone Tadaharu, Taira Yusuke, Arakaki Yoshihisa, Nakamura Rie, Oyama Takuma, Urasoe Chiaki, Kudaka Wataru, Aoki Yoichi

  The Journal of Obstetrics and Gynaecology Research ( John Wiley & Sons Australia, Ltd )  45 ( 8 ) 1724 - 1725   2019.08

   

• 帝王切開術後3年に発生した腟壁仮性動脈瘤 1症例報告(Vaginal artery pseudoaneurysm three years after cesarean section: A case report)

  Kinjo Yui, Kinjo Tadatsugu, Ooki Yuji, Yamada Hisako, Yara Nana, Taira Yusuke, Nitta Hayase, Urasoe Chiaki, Kudaka Wataru, Masamoto Hitoshi, Aoki Yoichi

  The Journal of Obstetrics and Gynaecology Research ( John Wiley & Sons Australia, Ltd )  45 ( 8 ) 1748 - 1749   2019.08

   

display all >>

SDGs 【 display / non-display 】

SDGs 【 display / non-display 】